What is the recommended management for severe Guillain‑Barré syndrome?

Management of Severe Guillain-Barré Syndrome

For severe GBS, initiate intravenous immunoglobulin (IVIg) at 0.4 g/kg daily for 5 days as first-line treatment, with plasma exchange (200-250 ml/kg over 5 sessions) as an equally effective alternative. 1

Immediate Assessment and ICU Admission

Admit patients to the ICU if they have any of the following 1:

• Respiratory distress with imminent respiratory insufficiency (inability to count to 15 in one breath, vital capacity <15-20 ml/kg or <1 L, use of accessory respiratory muscles)
• Severe autonomic cardiovascular dysfunction (arrhythmias, marked blood pressure variation)
• Severe swallowing dysfunction or diminished cough reflex
• Rapid progression of weakness

Use the Erasmus GBS Respiratory Insufficiency Score (EGRIS) to calculate the probability (1-90%) that a patient will require mechanical ventilation within 1 week. Up to 22% of GBS patients require mechanical ventilation within the first week of admission. 1

Immunotherapy Treatment

IVIg is the preferred first-line treatment because it is easier to administer, more widely available, and has lower discontinuation rates compared to plasma exchange, despite equal efficacy. 1, 2

Treatment Dosing:

• IVIg: 0.4 g/kg body weight daily for 5 consecutive days (total 2 g/kg)
• Plasma Exchange: 200-250 ml plasma/kg body weight in 5 sessions over 1-2 weeks

Critical Treatment Principles:

• Do NOT combine plasma exchange followed by IVIg - this provides no additional benefit 1, 3
• Do NOT use corticosteroids alone - eight randomized controlled trials showed no benefit, and oral corticosteroids had negative effects on outcome 1
• Do NOT use a second course of IVIg routinely for poor prognosis patients - no evidence supports this approach 2

Intensive Monitoring Protocol

Respiratory Monitoring (Critical Priority):

Apply the "20/30/40 rule" - patient is at risk of respiratory failure if 1:

• Vital capacity <20 ml/kg
• Maximum inspiratory pressure <30 cmH₂O
• Maximum expiratory pressure <40 cmH₂O

Monitor continuously for:

• Single breath count (≤19 predicts need for mechanical ventilation)
• Use of accessory respiratory muscles
• Vital capacity measurements

Neurological Monitoring:

• Assess muscle strength using Medical Research Council grading scale
• Document functional disability on GBS disability scale
• Monitor for swallowing and coughing difficulties

Autonomic Monitoring:

• Continuous electrocardiography
• Heart rate and blood pressure monitoring
• Bowel and bladder function assessment

Critical caveat: Two-thirds of GBS deaths occur during the recovery phase from cardiovascular and respiratory dysfunction. Maintain vigilant monitoring even after ICU discharge, especially in patients with cardiovascular risk factors. 1

Mechanical Ventilation Considerations

Risk factors for prolonged mechanical ventilation include 1:

• Inability to lift arms from bed at 1 week after intubation
• Axonal subtype on electrophysiology
• Unexcitable nerves on nerve conduction studies

Consider early tracheostomy in patients with these risk factors to reduce complications. 1

Complication Management

GBS-Specific Complications:

• Bulbar palsy: Assess swallowing safety, consider nasogastric feeding
• Facial palsy: Prevent corneal ulceration with eye protection
• Limb weakness: Prevent contractures, ossification, and pressure palsies through physiotherapy

Standard ICU Complications:

Implement standard preventive measures for:

• Pressure ulcers
• Hospital-acquired infections (pneumonia, UTIs)
• Deep vein thrombosis prophylaxis

Psychological and Pain Management:

Recognize that patients with complete paralysis maintain intact consciousness, vision, and hearing. 1

• Actively screen for pain, hallucinations, anxiety, and depression
• Consider gabapentinoids, tricyclic antidepressants, or carbamazepine for neuropathic pain 2
• Explain all procedures to reduce anxiety
• Be mindful of bedside conversations

Multidisciplinary Team Approach

Involve 1:

• Nurses (continuous monitoring)
• Physiotherapists (prevent contractures, respiratory therapy)
• Rehabilitation specialists
• Occupational therapists
• Speech therapists (swallowing assessment)
• Dietitians (nutritional support)

Managing Treatment Failure

About 40% of patients do not improve within 4 weeks of standard treatment. This does not mean treatment failed - progression might have been worse without therapy. 1

Treatment-Related Fluctuations (TRFs):

Occur in 6-10% of patients, defined as disease progression within 2 months after initial treatment-induced improvement. 1

For TRFs: Repeating the full course of IVIg or plasma exchange is common practice, though evidence is limited. This differs from insufficient initial response where repeating treatment is not recommended. 1

Acute-Onset CIDP:

If patients have ≥3 TRFs or clinical deterioration ≥8 weeks after onset, consider changing diagnosis to acute-onset CIDP (occurs in ~5% of cases). 1

Prognostic Assessment

Use the modified Erasmus GBS Outcome Score (mEGOS) on admission to predict functional outcome. 1, 2

Recovery expectations:

• Most patients show extensive recovery, even those who were tetraplegic or required prolonged mechanical ventilation
• Recovery continues for >3 years after onset
• Recurrence is rare (2-5%)